Meros Investment Management LP purchased a new position in shares of AtriCure, Inc. (NASDAQ:ATRC – Free Report) in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor purchased 170,000 shares of the medical device company’s stock, valued at approximately $4,756,600. Meros Investment Management LP owned 0.33% of AtriCure at the end of the most recent reporting period.
Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. BlackRock Inc. bought a new stake in AtriCure in the 2nd quarter valued at about $125,198,000. Osterweis Capital Management Inc. acquired a new stake in shares of AtriCure in the 2nd quarter valued at approximately $14,028,000. Marshall Wace LLP lifted its position in AtriCure by 63.4% during the 4th quarter. Marshall Wace LLP now owns 913,453 shares of the medical device company’s stock worth $36,136,000 after buying an additional 354,281 shares in the last quarter. Connor Clark & Lunn Investment Management Ltd. acquired a new position in AtriCure in the 2nd quarter valued at $9,388,000. Finally, Wellington Management Group LLP increased its position in AtriCure by 8.1% during the 3rd quarter. Wellington Management Group LLP now owns 4,292,087 shares of the medical device company’s stock worth $151,296,000 after purchasing an additional 322,818 shares in the last quarter. Institutional investors and hedge funds own 99.11% of the company’s stock.
Analyst Ratings Changes
Several brokerages have recently weighed in on ATRC. Piper Sandler lifted their price target on AtriCure from $50.00 to $60.00 and gave the company an “overweight” rating in a research report on Thursday. BTIG Research boosted their price target on shares of AtriCure from $45.00 to $55.00 and gave the company a “buy” rating in a report on Monday. Zacks Research downgraded shares of AtriCure from a “strong-buy” rating to a “hold” rating in a report on Monday. Canaccord Genuity Group raised their price objective on shares of AtriCure from $53.00 to $55.00 and gave the company a “buy” rating in a report on Wednesday, May 6th. Finally, UBS Group cut their target price on AtriCure from $55.00 to $50.00 and set a “buy” rating on the stock in a research report on Tuesday, July 28th. One analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating and four have issued a Hold rating to the company. According to MarketBeat.com, AtriCure has a consensus rating of “Moderate Buy” and a consensus price target of $49.89.
Insider Activity
In related news, Director Sven Wehrwein sold 25,000 shares of the business’s stock in a transaction on Tuesday, July 28th. The shares were sold at an average price of $37.84, for a total transaction of $946,000.00. Following the transaction, the director owned 40,518 shares of the company’s stock, valued at approximately $1,533,201.12. The trade was a 38.16% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, insider Karl S. Dahlquist sold 9,370 shares of the firm’s stock in a transaction dated Monday, August 24th. The stock was sold at an average price of $48.89, for a total value of $458,099.30. Following the transaction, the insider owned 87,319 shares in the company, valued at approximately $4,269,025.91. This trade represents a 9.69% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold 53,616 shares of company stock valued at $2,149,994 in the last 90 days. Insiders own 4.00% of the company’s stock.
AtriCure Price Performance
Shares of NASDAQ ATRC traded down $0.73 during midday trading on Friday, hitting $48.54. 236,457 shares of the company’s stock were exchanged, compared to its average volume of 789,958. AtriCure, Inc. has a 12-month low of $25.36 and a 12-month high of $49.98. The company has a current ratio of 4.22, a quick ratio of 3.19 and a debt-to-equity ratio of 0.14. The business’s fifty day moving average price is $37.50 and its two-hundred day moving average price is $32.14. The company has a market cap of $2.47 billion, a price-to-earnings ratio of 231.15 and a beta of 1.20.
AtriCure (NASDAQ:ATRC – Get Free Report) last posted its quarterly earnings data on Thursday, July 23rd. The medical device company reported $0.18 EPS for the quarter. AtriCure had a return on equity of 2.34% and a net margin of 1.85%.The firm had revenue of $153.60 million during the quarter, compared to analyst estimates of $151.80 million. During the same period in the prior year, the business posted ($0.13) EPS. AtriCure has set its FY 2026 guidance at 0.240-0.320 EPS. As a group, research analysts forecast that AtriCure, Inc. will post 0.29 EPS for the current fiscal year.
AtriCure Company Profile
AtriCure, Inc is a medical device company focused on the development, manufacture and marketing of innovative therapies to treat atrial fibrillation (AF) and related conditions. Founded in 2000 and headquartered in Mason, Ohio, AtriCure has established itself as a leader in surgical ablation devices designed to interrupt the errant electrical pathways that cause AF. The company’s solutions are used by cardiac surgeons and electrophysiologists to reduce the risk of stroke and improve patient outcomes in the treatment of both paroxysmal and persistent AF.
The company’s product portfolio centers on its Synergy Surgical Ablation System, which delivers controlled radiofrequency energy in a minimally invasive format, and the cryoICE Cryoablation System, which offers an alternative ablation modality using precise freezing techniques.
Featured Stories
- Five stocks we like better than AtriCure
- 3 Financial Stocks Positioned for the Fed’s Next Move After Jackson Hole
- IREN’s AI Pivot Looks Real, But the Market Wanted a Faster Payoff After Earnings
- Boeing’s $131B F-15 Win: Mach 1 Momentum or Just Altitude?
- Okta Stock Surges 29%—Is $200 the Next Stop?
Receive News & Ratings for AtriCure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AtriCure and related companies with MarketBeat.com's FREE daily email newsletter.
